|
Model Number UNK-NV-AXIUM |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Stroke/CVA (1770); Hematoma (1884); Rupture (2208)
|
Event Date 03/01/2018 |
Event Type
Injury
|
Event Description
|
Li w, ye m, cimpoca a, et al.Avenir® vs.Axium tm coils for the treatment of intracranial aneurysms: results of a multicenter randomized controlled trial with short-term follow-up.Frontiers in neurology.2022;12:817989.Doi:10.3389/fneur.2021.817989 medtronic literature review found a report of patient complications in association with axium coils.The purpose of this article was to compare the safety and efficacy of the avenir and axium passive mechanically detachable coil systems.The study was a prospective, multicenter, randomized controlled study carried out at ten medical centers from march 2018 to december 2019.A series of consecutive patients diagnosed with intracranial aneurysms were randomly assigned to undergo endovascular treatment with either the avenir or the axium mechanically detachable coil systems.The short-term outcomes from the two groups were compared with a focus on treatment efficacy and safety.A total of 161 patients were enrolled in the axium group.There were 50 males and 120 females with a mean age of 56.16 years and mean weight of 65.69 kg the following intra- or post-procedural outcomes were noted: -127 of the 131 aneurysms treated in patients in the axium group (96.95%) achieved the raymond-roy occlusion classification (rroc) of i (complete obliteration) or ii (residual neck).113/131 had complete aneurysm occlusion (rroc i), 14/131 rroc ii, and 4/131 had no aneurysm occlusion (rroc iii) -surgical complications were recorded up until the end of the 6-month follow-up period.In the axium group, two patients had a ruptured aneurysm, 14 had ischemic strokes, two exhibited incomplete aneurysm filling, and three developed hematomata at the puncture site.There were no procedure-associated patient deaths in the study.
|
|
Manufacturer Narrative
|
Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
|
Event Description
|
Additional information received reported that there were no such adverse events such as neurological impairment and death in the study.
|
|
Manufacturer Narrative
|
Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
|
Search Alerts/Recalls
|
|
|